Search Bar & Filters
Found 43 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying LTI-03, an experimental inhaled medication, for the treatment of Idiopathic Pulmonary Fibrosis IPF, a progressive and fatal lung disease that causes scarring and loss of lung function. The study aims to assess the safety, side effects, and potential benefits of LTI-03 in improving lung scarring and symptoms in patients diagnosed with IPF within the last five years. Participants on stable doses of certain approved IPF medications may join. The study is a Phase 2, randomized, double-blind, placebo-controlled trial comparing LTI-03 to a placebo. Participants will inhale LTI-03 or placebo capsules twice daily using a dry powder inhaler. The trial includes a 28-day screening period, a 24-week treatment period, and a 4-week follow-up. Lung scans will be done at the start and end of treatment, with several clinic visits throughout the study. Participants will attend up to nine clinic visits where lung function tests, blood samples for safety and disease markers, and questionnaires about IPF symptoms will be conducted. Safety will be monitored through physical exams, vital signs, heart tests, and tracking side effects and medication changes. The main outcome will measure safety by recording treatment-related side effects over 24 weeks, while lung function and lung scarring changes will also be evaluated.
Actively Recruiting
Researchers are studying UGN-104, a new form of UGN-101 also known as JELMYTO, to evaluate its safety and effectiveness for treating low-grade upper tract urothelial cancer LG-UTUC. This phase 3 study focuses on patients with this type of cancer located in the upper urinary tract. The research aims to understand how well UGN-104 works when placed directly into the affected area and to monitor its safety during treatment. Participants will receive UGN-104 once a week for six weeks, totaling six doses. This medication combines mitomycin with a special gel that becomes semi-solid at body temperature, allowing it to stay in the urinary tract longer. After about three months from the first dose, patients undergo evaluation to check for complete response, which includes urine tests and visual exams of the urinary tract. Those who respond completely may receive monthly maintenance doses of UGN-104 for up to 11 months. Patients who do not respond fully complete the study at this point. Throughout the study, participants will have regular clinic visits every three months for up to a year after their initial evaluation or until the cancer returns, worsens, or the patient passes away. Assessments include urine cytology, ureteroscopy, biopsies if needed, and laboratory tests to monitor mitomycin levels and side effects. Researchers will track treatment response duration, safety events, and drug concentrations to better understand the therapy and its effects over time.
Actively Recruiting
Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the safety and effects of the medicine Mevrometostat for treating RelapsedRefractory Small Cell Lung Cancer SCLC, Castration Resistant Prostate Cancer CRPC, and Follicular Lymphoma FL. This Phase 1 open-label study includes three parts, with Parts 1 and 2 closed for enrollment. Part 3, currently open, focuses on men with CRPC who have progressed after prior treatment. The study aims to understand how the study medicine behaves in the body and its impact on cancer. Participants in Part 3 receive Mevrometostat andor Enzalutamide. The study has two substudies a Bioequivalence BE substudy comparing two formulations of Mevrometostat, and a Drug-Drug Interaction DDI substudy with two cohorts. The BE substudy involves three single doses of Mevrometostat. The DDI substudy Cohort 1 takes Mevrometostat andor Itraconazole, and Cohort 2 combines Mevrometostat, Enzalutamide, and Itraconazole. After assessment phases, participants enter maintenance, taking Mevrometostat twice daily and Enzalutamide once daily until disease progression. Participants will visit the study center for dosing and monitoring, including evaluations of side effects, blood tests, and disease progression. The study measures dose-limiting toxicities, overall safety, and preliminary effectiveness using disease-specific criteria. Pharmacokinetics and patient-reported outcomes are also assessed at specific times. The study lasts approximately two years after the first participants visit, aiming to provide detailed safety and efficacy information.
Actively Recruiting
Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.
Actively Recruiting
Researchers are evaluating the antiviral effects of S-337395 compared to a placebo in adults who are not hospitalized but have respiratory syncytial virus RSV infection and are at high risk of progressing to severe disease. This phase 2b study focuses on participants starting treatment within 72 hours of RSV symptom onset to assess safety, tolerability, and efficacy. The trial includes adults with specific risk factors such as advanced age and chronic lung or cardiovascular diseases. Participants are randomly assigned to one of three groups a high dose of S-337395 taken orally twice daily for up to 5 days, a low dose of S-337395 taken with the same schedule, or a matching placebo given twice daily for 5 days. The study uses a double-blind design to compare the effects of these treatments. During the study, participants will undergo nasal swabs to measure changes in RSV viral load at multiple time points days 2, 4, and 6. Researchers will also monitor RSV symptom severity, time to symptom resolution, and the presence of the virus over the first 6 days. Safety is assessed by recording any treatment-emergent adverse events up to 28 days after starting treatment. Blood samples will measure the concentration of S-337395, and participants will be observed throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of secutrelvir for treating symptomatic nonhospitalized adults and adolescents with COVID-19 who are at high risk of developing severe disease. This phase 3 trial compares secutrelvir to a placebo to better understand its impact on preventing worsening illness and serious outcomes like hospitalization or death. Participants will be randomly assigned to receive either secutrelvir or a placebo. Both treatments are given orally as tablets. The study includes multiple assessments from baseline through 28 days, and safety monitoring continues up to 24 weeks after treatment. The trial is double-blind, so neither participants nor researchers know who receives the active drug or placebo. During the study, participants will be monitored for COVID-19 symptoms, viral levels, and health status through various measures such as symptom resolution times, medically attended visits, hospitalizations, and quality of life questionnaires. Blood samples will be collected on specific days to analyze drug levels and any side effects. The main outcome is to see how many participants experience worsening illness or serious events within 28 days of starting treatment.
1-10 of 43
1